Pliant Therapeutics to Participate in the Stifel Healthcare Conference
Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that Keith Cummings, M.D., Chief Financial Officer, and Greg ...
Promising Pipeline and Strong Financials Reinforce Buy Rating for Pliant Therapeutics
Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report), retaining the price ...
Business Insider3d
Buy Rating on Pliant Therapeutics Driven by Promising Bexotegrast Developments and Strategic Market Positioning
Analyst Faisal Khurshid of Leerink Partners reiterated a Buy rating on Pliant Therapeutics (PLRX – Research Report), retaining the price target of $33.00. Faisal Khurshid has given his Buy rating due ...